Dendreon to Present at 3rd Annual Cancer Immunotherapy Conference in New York 2012 Cancer Immunotherapy: A Long-Awaited Reality Conference Business Wire SEATTLE -- October 03, 2012 October 3, 2012 – Dendreon Corporation (NASDAQ:DNDN) today announced the company will be presenting at the MD Becker Partners’ 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York. Mark W. Frohlich, MD, executive vice president of research and development and chief medical officer at Dendreon, will provide an overview of PROVENGE^® (sipuleucel-T), the first FDA-approved autologous cellular immunotherapy for cancer. The presentation is expected to begin at 3:00 p.m. EDT. A live and archived webcast of the company's presentation at the conference, hosted by MD Becker Partners LLC, will be available at www.regonline.com/mdb2012. Dr. Frohlich will also participate in two panel sessions: *“Where Does Immunotherapy Fit into the Prostate Cancer Landscape?” - 9:00 a.m. EDT *“Cancer Vaccines - Past, Present and Future” - 11:00 a.m. EDT About the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference "Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy. AboutDendreon Dendreon Corporationis a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE^® (sipuleucel-T), was approved by the FDA inApril 2010. Dendreonis exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered inSeattle, Washington,and is traded on theNASDAQ Global Marketunder the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com. Contact: Dendreon Corporation Corporate Communications April Falcone, 206-829-1622 firstname.lastname@example.org
Dendreon to Present at 3rd Annual Cancer Immunotherapy Conference in New York
Press spacebar to pause and continue. Press esc to stop.